Evidence-based review of moxifloxacin

International Ophthalmology Clinics

Volumn 46, Issue 4, 2006, Pages 61-72

  O'Brien, Terrence P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BENZALKONIUM CHLORIDE; CEFUROXIME; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; POLYMYXIN B; POLYTRIM; TOBRAMYCIN; TRIMETHOPRIM;

CATARACT EXTRACTION; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; EYE INFECTIONS, BACTERIAL; HUMANS; OPHTHALMIC SOLUTIONS; QUINOLINES; TREATMENT OUTCOME;

EID: 33750356719     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000212139.62428.e6     Document Type: Review

References (36)

1. Vigamox [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2004.
2. Schentag JJ. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: Moxifloxacin and Streptococcus pneumoniae. J Chemother. 2002;14(suppl):13-21.
3. Metzler K, Hansen GM, Hedlin P, et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents. 2004;24:161-167.
4. McCulley JP, Lichtenstein SJ, Wagner RS, et al. A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues. Presented at the European Society of Cataract and Refractive Surgery 2006 Annual Meeting, London, England.
5. Wagner RS, Abelson MB, Shapiro A, et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol. 2005;123:1282-1283.
6. Kim T, Lane S, Holland E, et al. Human corneal stroma and epithelium concentrations of moxifloxacin and gatifloxacin following topical ocular dosing with Vigamox® and Zymar®. Paper presented at the Annual Meeting of the Ocular Microbiology and Immunology Group, October 15, 2005, Chicago, IL.
7. Holland EJ, Lane S, Kim T, et al. Human cornea and aqueous humor concentrations of moxifloxacin and gatifloxacin following ocular topical dosing with Vigamox® solution and Zymar®. Invest Ophthalmol Vis Sci. 2006;47(suppl):3577.
8. Kim DH, Stark WJ, O'Brien TP, et al. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112:1992-1996.
9. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2005;50(suppl 1):S32-S45.
10. Mather R, Karenchak LM, Romanowski EG, et al. Fourth-generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
11. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.
12. Kowalski RP, Yates KA, Romanowski EG, et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005b;112:1987-1991.
13. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med. 2003;348:1112-1121.
14. Centers for Disease Control and Prevention. Outbreak of bacterial conjunctivitis at a college: New Hampshire, January-March, 2002. Morb Mortal Wkly Rep. 2002;51:205-207.
15. Minnesota Department of Health. Outbreak of conjunctivitis due to Streptococcus pneumoniae. Disease Control Newsletter. 2004;32:6-8.
16. Centers for Disease Control and Prevention. Pneumococcal conjunctivitis at an elementary school: Main, September 20-December 6, 2002. Morb Mortal Wkly Rep. 2003;52:64-66.
17. Lichtenstein SJ, Dorfman M, Kennedy R, et al. Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2006;43:19-26.
18. Kowalski RP, Romanowski EG, Mah FS, et al. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol. 2004;138:33-37.
19. Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140:497-594.
20. Barry P, Seal DV, Gettinby G, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery. J Cataract Ref Surg. 2006;32:407-410.
21. Fernandez de Castro LE, Sandoval HP, Vroman DT, et al. Prevention of Staphylococcus aureus endophthalmitis by topical gatifloxacin in rabbit prophylaxis model [abstract]. Invest Ophthalmol Vis Sci. 2006;47(suppl):3559.
22. Kowalski RP, Kowalski BR, Thompson PP, et al. The preservative effects of "antibiotic concentration" and "addition of BAK" on the time-kill comparison of moxifloxacin and gatifloxacin [abstract]. Invest Ophthalmol Vis Sci. 2006;47(suppl):1888.
23. Schlech BA, Sutton A, Rosenthal RA, et al. Antimicrobial preservative effectiveness of Vigamox® [abstract]. Invest Ophthalmol Vis Sci. 2004;45(suppl):4913.
24. Borsos SD, Blondeau JM. Antimicrobial efficacy of gatifloxacin with and without benzalkonium chloride compared with moxifloxacin against common ocular pathogens [abstract]. Invest Ophthalmol Vis Sci. 2006;47(suppl):1892.
25. Blondeau J, Brosos S. Antimicrobial efficacy of gatifloxacin with and without benzalkonium chloride compared with moxifloxacin against methicillin-resistant Staphylococcus aureus [abstract]. Invest Ophthalmol Vis Sci. 2006;47(suppl):1903.
26. Owen GR, Dembinska O, Stout KR, et al. Corneal penetration and change in corneal permeability of moxifloxacin versus gatifloxacin [abstract]. Invest Ophthalmol Vis Sci. 2004;45(suppl):4910.
27. McGee DH, Holt WF, Kastner PR, et al. Safety of moxifloxacin as shown in animal and in vitro studies. Survey Ophthalmol. 2005;50:S46-S54.
28. Bergamini MVW, Heaton J, McGee D, et al. A three-month topical ocular toxicity study of moxifloxacin ophthalmic solutions in cynomolgus monkeys [abstract]. Invest Ophthalmol Vis Sci. 2003;44(suppl):4457.
29. Dembinska O, Stout K, Griffin J, et al. Preservation of the retinal function following a single intravitreal injection of Vigamox® solution in non-human primates [abstract]. Invest Ophthalmol Vis Sci. 2006;47(suppl):4681.
30. Griffin JM, Dembinska R, Rice RL, et al. A ten-week toxicity evaluation of Vigamox® (0.5% moxifloxacin solution) following a single intravitreal injection in nonhuman primates [abstract]. Invest Ophthalmol Vis Sci. 2006;47(suppl):3578.
31. Yee RW, Sorour HM, Yee SB, et al. Comparison of relative toxicity of four ophthalmic antibiotics using the human cornea epithelial cell culture system [abstract]. Invest Ophthalmol Vis Sci. 2004;45(suppl):4939.
32. Solomon R, Donnenfeld ED, Perry HD, et al. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% on corneal epithelial wound healing after photorefractive keratectomy [abstract]. Invest Ophthalmol Vis Sci. 2005;46(suppl):4895.
33. Burka JM, Bower KS, Van Roekel RC, et al. The effect of fourth-generation fluoroquinolones, gatifloxacin and moxifloxacin, on epithelial healing following photorefractive keratectomy (PRK). Am J Ophthalmol. 2005;140:83-87.
34. Yee RW, Setabutr P, Foltermann MO, et al. The effects of topical moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution on corneal healing after bilateral photorefractive keratectomy. Cornea. In press.
35. Durrie DS, Trattler W. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocular Pharmacol Ther. 2005;21:236-241.
36. Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin, ophthalmic solution 0.5% Vigamox® in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol. 2005;50:S55-S63.